Evidence map›Paper›PMID 37352334›Full record

ArticlePLoS pathogens2023

Deficiency in Galectin-3, -8, and -9 impairs immunity to chronic Mycobacterium tuberculosis infection but not acute infection with multiple intracellular pathogens.

Huntly M Morrison, Julia Craft, Rafael Rivera-Lugo, Jeffery R Johnson, Guillaume R Golovkine, Samantha L Bell, Claire E Dodd, Erik Van Dis, Wandy L Beatty, Shally R Margolis and 10 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Increased Levels of Galectin-3 in Critical COVID-19.International journal of molecular sciences · 2023
    Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 1 country.

Huntly M MorrisonDepartment of Molecular and Cell Biology, Division of Immunology and Molecular Medicine, University of California, Berkeley, Berkeley, California, United States of America.
Julia CraftDepartment of Internal Medicine, Division of Infectious Diseases, University of California, Davis, Davis, California, United States of America.
Rafael Rivera-LugoDepartment of Molecular and Cell Biology, Division of Immunology and Molecular Medicine, University of California, Berkeley, Berkeley, California, United States of America.
Jeffery R JohnsonDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco; Quantitative Biosciences Institute (QBI), University of California, San Francisco; Gladstone Institutes, San Francisco, California, United States of America.
Guillaume R GolovkineDepartment of Molecular and Cell Biology, Division of Immunology and Molecular Medicine, University of California, Berkeley, Berkeley, California, United States of America.
Samantha L BellDepartment of Microbial Pathogenesis and Immunology, Texas A&M Health, School of Medicine, Bryan, Texas, United States of America.
Claire E DoddDepartment of Molecular and Cell Biology, Division of Immunology and Molecular Medicine, University of California, Berkeley, Berkeley, California, United States of America.
Erik Van DisDepartment of Molecular and Cell Biology, Division of Immunology and Molecular Medicine, University of California, Berkeley, Berkeley, California, United States of America.
Wandy L BeattyDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Shally R MargolisDepartment of Molecular and Cell Biology, Division of Immunology and Molecular Medicine, University of California, Berkeley, Berkeley, California, United States of America.
Teresa RepasyDepartment of Molecular and Cell Biology, Division of Immunology and Molecular Medicine, University of California, Berkeley, Berkeley, California, United States of America.
Isaac ShakerDepartment of Internal Medicine, Division of Infectious Diseases, University of California, Davis, Davis, California, United States of America.
Angus Y LeeCancer Research Laboratory, University of California, Berkeley, Berkeley, California, United States of America.
Russell E VanceDepartment of Molecular and Cell Biology, Division of Immunology and Molecular Medicine, University of California, Berkeley, Berkeley, California, United States of America.
Sarah A StanleyDepartment of Molecular and Cell Biology, Division of Immunology and Molecular Medicine, University of California, Berkeley, Berkeley, California, United States of America.
Robert O WatsonDepartment of Microbial Pathogenesis and Immunology, Texas A&M Health, School of Medicine, Bryan, Texas, United States of America.
Nevan J KroganDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco; Quantitative Biosciences Institute (QBI), University of California, San Francisco; Gladstone Institutes, San Francisco, California, United States of America.
Daniel A PortnoyDepartment of Molecular and Cell Biology, Division of Immunology and Molecular Medicine, University of California, Berkeley, Berkeley, California, United States of America.
Bennett H PennDepartment of Internal Medicine, Division of Infectious Diseases, University of California, Davis, Davis, California, United States of America.
Jeffery S CoxDepartment of Molecular and Cell Biology, Division of Immunology and Molecular Medicine, University of California, Berkeley, Berkeley, California, United States of America.ORCID 0000-0002-5061-6618
University of California, Berkeley · USUniversity of California, Davis · USQB3 · USTexas A&M Health Science Center · USHoward Hughes Medical Institute · USWashington University in St. Louis · US

Funding

The role of Listeria cyclic-di-AMP during infection and immunityP01AI063302 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI PORTNOY, DANIEL A · 2004 to 2025
$45.5M
RESEARCH PROJECT 2U19AI135990 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JEFFERY S COX · 2018 to 2026
$21.4M
Systems Biology, Bioinformatics, & Data IntegrationU19AI162583 · NIAID · UNIVERSITY OF WASHINGTON · PI COX, JEFFERY S, HAWN, THOMAS R · 2021 to 2025
$13.0M
Listeria Hemolysis and Escape From a VacuoleR01AI027655 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI DANIEL A PORTNOY · 1993 to 2026
$10.1M
Functional and Structural Dissection of Inflammasome ActivationR37AI075039 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI RUSSELL E VANCE · 2018 to 2026
$3.8M
Understanding How the Ubiquitin Ligase CBL Regulates Innate Immune ResponsesR01AI144149 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PENN, BENNETT · 2019 to 2023
$2.4M
Automated High-Throughput, High-Content Confocal/Wide-Field Microscope SystemS10OD021828 · OD · UNIVERSITY OF CALIFORNIA BERKELEY · PI WEST, MARY · 2017 to 2017
$1.0M
NIAID NIH HHS P01 AI063302NIAID NIH HHS R01 AI027655NIAID NIH HHS R01 AI144149NIAID NIH HHS R37 AI075039NIAID NIH HHS U19 AI135990NIAID NIH HHS U19 AI162583NIH HHS S10 OD021828
6 · The paper itself

Abstract

Macrophages employ an array of pattern recognition receptors to detect and eliminate intracellular pathogens that access the cytosol. The cytosolic carbohydrate sensors Galectin-3, -8, and -9 (Gal-3, Gal-8, and Gal-9) recognize damaged pathogen-containing phagosomes, and Gal-3 and Gal-8 are reported to restrict bacterial growth via autophagy in cultured cells. However, the contribution of these galectins to host resistance during bacterial infection in vivo remains unclear. We found that Gal-9 binds directly to Mycobacterium tuberculosis (Mtb) and Salmonella enterica serovar Typhimurium (Stm) and localizes to Mtb in macrophages. To determine the combined contribution of membrane damage-sensing galectins to immunity, we generated Gal-3, -8, and -9 triple knockout (TKO) mice. Mtb infection of primary macrophages from TKO mice resulted in defective autophagic flux but normal bacterial replication. Surprisingly, these mice had no discernable defect in resistance to acute infection with Mtb, Stm or Listeria monocytogenes, and had only modest impairments in bacterial growth restriction and CD4 T cell activation during chronic Mtb infection. Collectively, these findings indicate that while Gal-3, -8, and -9 respond to an array of intracellular pathogens, together these membrane damage-sensing galectins play a limited role in host resistance to bacterial infection.

Indexed as

Mycobacterium tuberculosisTuberculosisAnimalsGalectin 3GalectinsMacrophagesMiceMice, KnockoutSalmonella typhimuriumGalectin 3Galectins

Identifiers

PMID37352334
PMCPMC10325092
OpenAlexW4381839580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.